MarketBeat provided consensus price targets and ratings, while DBV Technologies and XTL Biopharmaceuticals compete in the small-cap healthcare market.
1 report, 1 independent
Updated Sep 22
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
MarketBeat provided consensus price targets and ratings, while DBV Technologies and XTL Biopharmaceuticals compete in the small-cap healthcare market.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
MarketBeat
American personal finance blog
-
DBV Technologies
publicly owned French biopharmaceutical firm headquartered in Bagneux, France
Related events
- Avita Medical received a buy rating reaffirmation from TD Cowen, alongside MarketBeat consensus ratings and SEC insider buying disclosures.
- MarketBeat reported the consensus rating for Diaceutics PLC.
- MarketBeat reported a consensus rating for SKYX Platforms, a company listed on the Nasdaq exchange.
- MarketBeat reports consensus price targets for Merchants Bancorp and WesBanco, identifying both as mid-cap finance companies.
- MarketBeat reported analyst recommendations for Cytokinetics and Gain Therapeutics, two competing healthcare companies.